Navigation Links
Uroplasty Reports Fiscal Second Quarter 2013 Financial Results

MINNEAPOLIS, Oct. 25, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the second quarter of fiscal 2013 ended September 30, 2012.

Global sales grew 15% to $5.7 million for the second quarter of fiscal 2013, compared with $5.0 million in the fiscal second quarter a year ago. Sales in the U.S. increased 23%, driven by a 38% increase in sales of the Urgent® PC Neuromodulation System. U.S. sales of Macroplastique were up 4% from the prior year.

"The fiscal second quarter results continued to demonstrate the success of our efforts with Urgent PC sales in the U.S.," said David Kaysen, President and CEO of Uroplasty. "The number of active Urgent PC customers in the U.S. increased sequentially in the second quarter to a record 648 from 577 in the fiscal first quarter. Additionally, we sold 3,576 lead set boxes in the fiscal second quarter compared with 3,283 in the fiscal first quarter." 

U.S. Urgent PC Sales in the fiscal second quarter totaled $2.7 million, up from $2.5 million in the fiscal first quarter of 2013.  Just as the quarter ended, Noridian, one of the Regional Medicare carriers, expanded coverage of Urgent PC treatments from twelve months to two years for the 3.6 million covered Medicare lives in its jurisdiction. This change in policy was the result of a review of published data, showing the positive results of using Urgent PC over a 24-month period. Noridian provides Medicare services in Alaska, Arizona, Idaho, Montana, North Dakota, Oregon, South Dakota, Utah, Washington, and Wyoming. Uroplasty also benefited from published reimbursement coverage policies for percutaneous tibial nerve stimulation (PTNS) treatments by private insurance carriers EmblemHealth, covering approximately 2.1 million lives in New York and New Jersey, and ConnectiCare, covering approximately 228,000 lives in Connecticut.

"In addition to continued expansion of reimbursement, we have had further positive clinical data released on Urgent PC.  The 3-year STEP Study data was presented for the first time at the Western Section American Urological Association conference in Hawaii earlier this month. This multi-center study demonstrated that patients who respond to the initial 12 weeks of Urgent PC therapy sustained their symptom improvement over 3 years," said Mr. Kaysen.

Macroplastique sales in the U.S. totaled $1.4 million in the fiscal second quarter, up 4% over the same quarter last year. "Over the past year, we have successfully built our share in the bulking market and during fiscal 2013 we anticipate steady sales from Macroplastique," Mr. Kaysen commented.

Net sales to customers outside of the U.S. for the fiscal second quarter totaled $1.5 million, a decrease of 3% from the prior fiscal year's second quarter.  Excluding the impact of fluctuations in foreign currency exchange rates, total sales outside the U.S. were up 6%.  Urgent PC sales outside of the U.S. of $510,000 increased 31% from $389,000 in the prior fiscal year's second quarter. Excluding the impact of fluctuations in foreign currency exchange rates, Urgent PC sales increased 40%.

The Company reported an operating loss of $642,000 in the fiscal second quarter, compared with a $1.3 million operating loss in the same quarter last year. Excluding non-cash charges for share-based compensation and depreciation and amortization expense, the non-GAAP operating loss was $163,000 in the second quarter of fiscal 2013, compared with an $837,000 non-GAAP operating loss in the second quarter a year ago.  The decrease in operating loss was primarily attributable to the increase in sales and improved gross margin, which more than offset the increase in operating expenses.

For the six-month period ended September 30, 2012, sales grew 17% to $11.3 million, reflecting a 31% increase in U.S. sales and a 9% decrease in sales outside the U.S.  In the U.S., sales of Urgent PC increased 49% to $5.3 million and Macroplastique sales grew 10% to $2.9 million.  At September 30, 2012, cash, cash equivalents and cash investments totaled $15.4 million. 

"We are pleased to report that we have initiated our pilot study in the U.S. to evaluate the efficacy of Urgent PC for the treatment of bowel incontinence," continued Mr. Kaysen. "We are currently enrolling patients at one of the two study sites. We are also moving forward with our efforts to secure a CE Mark in Europe for an implantable tibial nerve stimulator for the treatment of over active bladder. At the recent International Continence Society meeting in Beijing, China, the results of a nine-year study were presented that demonstrated the durability and safety of an implantable tibial nerve neuromodulation device." 

"As we look ahead, we expect continued sequential growth of Urgent PC sales. To that end, we added three sales reps during the quarter to end with a total of 41. We plan to add three more reps by the end of the fiscal year. We are optimistic about the outlook for our financial performance for fiscal 2013. Reimbursement coverage is expanding, clinical data continue to be positive, and we have an experienced sales organization and solid infrastructure in place to support our growth. Our team is focused on our plan to drive Urgent PC sales and increase utilization," Mr. Kaysen concluded.

Conference CallUroplasty will host an audio conference call today at 3:30 pm Central, 4:30 pm Eastern, to review the financial results for the fiscal second quarter of 2013.  David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will host the call. Individuals wishing to participate in the conference call should dial 877-941-0843. An audio replay will be available for 30 days following the call at 800-406-7325 with the passcode 4568214#.

About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians.  Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at

Forward-Looking InformationThis press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that we will ever achieve sustained profitability, that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment or that existing carriers and payers will not change their coverage decisions, that the rate of adoption of our products by new customers will continue, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.For Further Information: Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and



EVC Group

Jenifer Kirtland/Jamar Ismail (Investors)


Chris Gale (Media)

646.201.5431  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)Three Months EndedSix Months EndedSeptember 30,September 30,2012201120122011Net sales

$5,709,840$4,967,621$11,286,963$9,620,743Cost of goods sold 

774,963759,3361,530,5501,468,901Gross profit

4,934,8774,208,2859,756,4138,151,842Operating expensesGeneral and administrative

1,027,835942,5572,119,6811,964,415Research and development

598,933456,8711,161,974912,631Selling and marketing


215,681214,056431,290426,3715,576,4915,483,35911,411,82210,767,434Operating loss

(641,614)(1,275,074)(1,655,409)(2,615,592)Other income (expense)Interest income

10,93113,71623,50931,550Interest expense

-(57)-(57)Foreign currency exchange gain (loss)

5,794(8,587)(3,877)(3,279)16,7255,07219,63228,214Loss before income taxes

(624,889)(1,270,002)(1,635,777)(2,587,378)Income tax expense 

14,6378,48523,10422,416Net loss

$(639,526)$(1,278,487)$(1,658,881)$(2,609,794)Basic and diluted loss per common share

$(0.03)$(0.06)$(0.08)$(0.13)Weighted average common shares outstanding:Basic and diluted

20,763,34520,688,91920,753,36820,659,017UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)September 30, 2012March 31, 2012AssetsCurrent assets:Cash and cash equivalents & short-term investments

$15,175,304$11,854,127Accounts receivable, net



465,568363,639Total current assets

19,087,56015,620,942Property, plant, and equipment, net

1,087,1821,171,979Intangible assets, net 

519,030945,880Long-term investments

240,0004,429,140Deferred tax assets

117,456122,872Total assets

$21,051,228$22,290,813Liabilities and Shareholders' EquityCurrent liabilities:Accounts payable

$614,919$593,585Current portion – deferred rent

35,00035,000Income tax payable

6,48017,892Accrued liabilities:Compensation


407,074316,995Total current liabilities

2,565,4682,539,619Deferred rent – less current portion

23,66942,043Accrued pension liability

424,481474,396Total liabilities

3,013,6183,056,058Total shareholders' equity

18,037,61019,234,755Total liabilities and shareholders' equity

$21,051,228$22,290,813 UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)Six Months EndedSeptember 3020122011Cash flows from operating activities:Net loss

$(1,658,881)$(2,609,794)Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization

576,665552,275 Loss on disposal of  equipment

2,7976,475 Amortization of premium on marketable securities

26,71617,039 Share-based consulting expense

1,6232,787 Share-based compensation expense

353,060288,754 Deferred income tax expense (benefit)

2,860(3,040) Deferred rent credit

(18,374)(17,614) Changes in operating assets and liabilities:Accounts receivable, net


(175,833)(65,281)Other current assets

(102,998)(143,370)Accounts payable

26,516(27,130)Accrued liabilities

10,040(20,515)Accrued pension liability, net

(36,401)(65,303)Net cash used in operating activities

(891,673)(2,281,152)Cash flows from investing activities: Proceeds from maturity of held-to-maturity investments

3,800,0003,500,016 Proceeds from maturity of available-for-sale investments

2,000,0007,518,252 Purchases of held-to-maturity investments

(1,780,000)(5,280,042) Purchases of available-for-sale investments

(3,218,286)- Purchases of property, plant and equipment

(93,981)(106,325) Proceeds from sale of property, plant and equipment

7,276- Purchase of intangible assets

(4,440)(67,198)Net cash provided by investing activities

710,5695,564,703Cash flows from financing activities: Net proceeds from exercise of options

150,000207,050Net cash provided by financing activities

150,000207,050Effect of exchange rate changes on cash and cash equivalents

(10,580)(15,824)Net (decrease) increase  in cash and cash equivalents

(41,684)3,474,777Cash and cash equivalents at beginning of period

4,653,2266,063,573Cash and cash equivalents at end of period

$4,611,542$9,538,350Cash paid during the period for interest

$-$57Cash paid during the period for income taxes

35,50724,074Non-GAAP Financial Measures:  The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss.  The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP.  We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies.  Therefore, our non-GAAP financial measures may not be comparable to those used by other companies.  We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.

We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes and incentive compensation for senior management because we believe such measures are one important indicator of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss during the three months ended September 30, 2012 and 2011 was approximately $163,000 and $837,000, respectively.  Our non-GAAP operating loss during the six months ended September 30, 2012 and 2011 was approximately $724,000 and $1.8 million, respectively.  The decrease in non-GAAP operating loss for the three and six months ended September 30, 2012 over the corresponding period a year ago is attributed to the increase in net sales and gross profit percent, which more than offset the increase in operating spending.Expense AdjustmentsThree Months EndedGAAPShare-based  ExpenseDepreciationAmortization of IntangiblesNon-GAAPSeptember 30, 2012Gross Profit



$9,000$4,952,000% of net sales

86.4%86.7%Operating ExpensesGeneral and administrative



(50,000)870,000Research and development



(1,000)584,000Selling and marketing









5,115,000Operating Loss





$(163,000)September 30, 2011Gross Profit



$8,000$4,222,000% of net sales

84.7%85.0%Operating ExpensesGeneral and administrative



(40,000)812,000Research and development



(3,000)443,000Selling and marketing









5,059,000Operating Loss





$(837,000)Expense AdjustmentsSix Months EndedGAAPShare-based  ExpenseDepreciationAmortization of IntangiblesNon-GAAPSeptember 30, 2012Gross Profit



$18,000$9,789,000% of net sales

86.4%86.7%Operating ExpensesGeneral and administrative



(96,000)1,830,000Research and development



(2,000)1,134,000Selling and marketing









10,513,000Operating Loss





$(724,000)September 30, 2011Gross Profit



$15,000$8,178,000% of net sales

84.7%85.0%Operating ExpensesGeneral and administrative



(80,000)1,721,000Research and development



(6,000)888,000Selling and marketing









9,950,000Operating Loss






SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty To Participate In Two Upcoming Conferences
2. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
3. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
4. Uroplasty To Present At The JMP Securities Healthcare Conference
5. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
6. Uroplasty Announces Product Development and New Clinical Trial Initiatives
7. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
8. Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2012
9. Zimmer Holdings, Inc. Reports Third Quarter 2012 Financial Results
10. Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
11. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
Post Your Comments:
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
Breaking Medicine News(10 mins):